Clinical trials
for patients
Learn about available clinical trials
-
July 21, 2025Pamplona/MadridIn recruitmentEarly phase
GEM-AnitoFIRST Clinical trial to evaluate the efficacy and safety of Antinocabtagene Autoleucel in participants with newly diagnosed multiple myeloma.
The aim of this study is to investigate the safety and efficacy of Dara-VRD (cohort A) or Isa- VRd (cohorts B and C) treatment followed by anitocabtagene autoleucel, a CAR-T therapy, coupled with lenalidomide maintenance treatment (cohorts A and B) in patients with newly diagnosed MM. -
July 16, 2025Pamplona/MadridIn recruitmentEarly phase
IOV-LUN-202 Clinical trial of autologous tumor infiltrating lymphocytes (LN-145) in patients with metastatic non-small cell lung cancer
The objective of this study is to test an investigational new treatment for participants with non-small cell lung cancer. -
July 16, 2025PamplonaIn recruitment
996 Randomized, double-blind, multicenter, placebo-controlled Phase III trial to evaluate the efficacy and safety of trimodulin (BT588) in hospitalized adult subjects with severe community-acquired pneumonia (CAP)
The purpose of this clinical trial is to test whether trimodulin (the trial drug) works and whether it is safe to treat people with severe community-acquired pneumonia (CAP) when given with the standard of care. The reference treatments refer to the most common treatments given to people who are hospitalized with CAP and need mechanical ventilation to breathe. -
July 16, 2025Pamplona/MadridIn recruitmentEarly phase
CYTB323L12201 Clinical trial to assess the efficacy and safety of rapcabtagene autoleucel vs. reference therapy in patients suffering from systemic lupus erythematosus erythematosus with active refractory lupus nephritis
The purpose of the study is to find out if YTB323 is safe and effective (if it can help) in people with SLE and NL. -
July 16, 2025PamplonaIn recruitmentEarly phase
CLOU064M12101 A 12-week exploratory study to evaluate the efficacy and safety and explore the mechanism of action of remibrutinib (LOU064) in adult patients with chronic urticaria
The purpose of the study is to learn more about remibrutinib in the treatment of chronic inducible urticaria and chronic spontaneous urticaria in adults. It will evaluate whether it is safe, well tolerated and effective and also explore how remibrutinib acts in the body and on the skin. -
July 16, 2025Pamplona/MadridIn recruitmentEarly phase
LCB-2301-002 Clinical trial of nilk-2301, a bispecific antibody that binds ceacam5 x cd3, in combination with ni-1801 or nilk-2301 plus standard treatment in pancreatic cancer patients.
The objective of this study is to evaluate whether the study drug, NILK-2301 in combination with NI-1801 or treatment as usual, has potential beneficial effects and is safe for patients with this type of cancer. -
July 10, 2025PamplonaIn recruitment
VRDN-003-303 Randomized, double-masked, controlled study to evaluate the safety and tolerability of VRDN-003 in participants with thyroid eye disease (TOD).
The purpose of the study, which involves research, is to determine whether VRDN-003, the experimental investigational drug, is safe and tolerable (i.e., whether the body reacts acceptably to VRDN-003) in participants with EOT when administered as a series of subcutaneous (SC) injections (given by needle into the layer of fat between the skin and muscle). -
July 3, 2025MadridIn recruitmentEarly phase
DS6000-126 Phase II clinical trial to evaluate the efficacy and safety of Raludotatug Deruxtecan (R-DXd) in advanced or metastatic solid tumors
The main objective is to evaluate the efficacy of R-DXd treatment as measured by ORR as assessed by the investigator. -
July 3, 2025MadridIn recruitmentEarly phase
BAY 2927088 / 22752 Clinical trial with BAY 2927088 tablets for in patients who have a solid tumor with human epidermal growth factor receptor 2 mutations
The main objective is to evaluate the efficacy of BAY 2927088 in objective response rate (ORR) assessed by blinded independent centralized review (BICR). -
July 3, 2025Pamplona/MadridIn recruitment
ART0380C001 Trial of ART0380 as oral and gemcitabine treatment in patients with advanced or metastatic solid tumor
The study is being conducted to answer the following questions: What is the highest dose of ART0380 that can be administered along with a standard dose of gemcitabine to cancer patients without causing significant side effects (also known as the "recommended dose")? How often can the study products be administered to cancer patients? What are the side effects of each of the study products? What are the side effects of the combination? How do the study products affect biomarkers? Can th...